194 articles – 65 Notices  [english version]
Fiche concise
Obesity phenotypes in midlife and cognition in early old age: The Whitehall II cohort study.
Singh-Manoux A., Czernichow S., Elbaz A., Dugravot A., Sabia S., Hagger-Johnson G., Kaffashian S., Zins M., Brunner E. J., Nabi H. et al
Neurology Journal 79, 8 (2012) 755-62 - http://www.hal.inserm.fr/inserm-00725475
 (22915175) 
Obesity phenotypes in midlife and cognition in early old age: The Whitehall II cohort study.
Archana Singh-Manoux () 1, 2, 3, Sébastien Czernichow1, 4, Alexis Elbaz5, Aline Dugravot1, Séverine Sabia2, Gareth Hagger-Johnson2, Sara Kaffashian1, Marie Zins1, Eric Brunner2, Hermann Nabi1, Mika Kivimäki2
1 :  CESP - Centre de recherche en épidémiologie et santé des populations
INSERM : U1018 – Université Paris XI - Paris Sud – Hôpital Paul Brousse – Assistance publique - Hôpitaux de Paris (AP-HP)
16 avenue Paul Vaillant Couturier 94807 Villejuif Cedex, France
France
2 :  Department of Epidemiology and Public Health
http://www.ucl.ac.uk/epidemiology/staff/singh-manoux.htm
University College of London (UCL)
1-19 Torrington Place London WC1E 6BT
Royaume-Uni
3 :  Centre de Gérontologie
Assistance publique - Hôpitaux de Paris (AP-HP) – Hôpital Sainte Périne
France
4 :  Service de nutrition
Assistance publique - Hôpitaux de Paris (AP-HP) – Hôpital Ambroise Paré
Boulogne-Billancourt
France
5 :  Neuroépidémiologie
INSERM : U708 – Université Pierre et Marie Curie [UPMC] - Paris VI
GH Pitie-Salpetriere 47, Boulevard de L'Hopital 75651 PARIS CEDEX 13
France
OBJECTIVE: To examine the association of body mass index (BMI) and metabolic status with cognitive function and decline. METHODS: A total of 6,401 adults (71.2% men), aged 39-63 years in 1991-1993, provided data on BMI (normal weight 18.5-24.9 kg/m(2), overweight 25-29.9 kg/m(2); and obese ≥30 kg/m(2)) and metabolic status (abnormality defined as 2 or more of 1) triglycerides ≥1.69 mmol/L or lipid-lowering drugs, 2) systolic blood pressure ≥130 mm Hg, diastolic blood pressure ≥85 mm Hg, or antihypertensive drugs, 3) glucose ≥5.6 mmol/L or medications for diabetes, and 4) high-density lipoprotein cholesterol <1.04 mmol/L for men and <1.29 mmol/L for women). Four cognitive tests (memory, reasoning, semantic, and phonemic fluency) were administered in 1997-1999, 2002-2004, and 2007-2009, standardized to z scores, and averaged to yield a global score. RESULTS: Of the participants, 31.0% had metabolic abnormalities, 52.7% were normal weight, 38.2% were overweight, and 9.1% were obese. Among the obese, the global cognitive score at baseline (p = 0.82) and decline (p = 0.19) over 10 years was similar in the metabolically normal and abnormal groups. In the metabolically normal group, the 10-year decline in the global cognitive score was similar (p for trend = 0.36) in the normal weight (-0.40; 95% confidence interval [CI] -0.42 to -0.38), overweight (-0.42; 95% CI -0.45 to -0.39), and obese (-0.42; 95% CI -0.50 to -0.34) groups. However, in the metabolically abnormal group, the decline on the global score was faster among obese (-0.49; 95% CI -0.55 to -0.42) than among normal weight individuals (-0.42; 95% CI -0.50 to -0.34), (p = 0.03). CONCLUSIONS: In these analyses the fastest cognitive decline was observed in those with both obesity and metabolic abnormality.
Sciences du Vivant/Santé publique et épidémiologie
Anglais
0028-3878

Articles dans des revues avec comité de lecture
10.1212/WNL.0b013e3182661f63
Neurology Journal (Neurology)
Publisher American Academy of Neurology (AAN)
ISSN 0028-3878 (eISSN : 1526-632X)
internationale
21/08/2012
79
8
755-62

Study Funding: NIH (R01AG013196; R01AG034454, R01HL036310), Academy of Finland, the BUPA Foundation, UK; Medical Research Council (G0902037), UK.